COMMUNIQUÉS West-GlobeNewswire

Instil Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update
15/05/2026
DALLAS, May 15, 2026 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a biotechnology company focused on identifying and advancing innovative therapeutics, today reported its first quarter 2026 financial [...]
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
15/05/2026
BEDFORD, Mass., May 15, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” or the “Company”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced [...]
Traws Pharma Provides Business Highlights and Reports Q1 2026 Financial Results
15/05/2026
Private financing of up to $60M offering of common stock (with $10M upfront) and milestone-based warrants expected to support operations into Q1 2027 Tivoxavir marboxil advancing towards a human influenza challenge [...]
BioXcel Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results
15/05/2026
FDA accepted sNDA for IGALMI® use in at-home (outpatient) setting; set Nov. 14, 2026, as PDUFA date Advancing BXCL501 as a potential acute treatment for agitation associated with Alzheimer’s dementia Evaluating [...]
Satellos Reports First Quarter 2026 Financial Results and Highlights Company Progress
15/05/2026
Eleven clinical trial sites in BASECAMP currently active; remaining planned sites to be activated throughout Q2 2026 BASECAMP remains on track to complete enrollment in Q3 2026 The Company has initiated the TRAILHEAD [...]
Indaptus Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
15/05/2026
NEW YORK, May 15, 2026 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical-stage biotechnology company, today announced financial results for the first quarter ended [...]
Telix Announces Collaborations to Explore PSMA-PET Imaging in Emerging Prostate Cancer Treatment Approaches
15/05/2026
Telix to partner with companies developing advanced minimally invasive and image-guided ablative technologies for prostate cancer. Initial focus on patient selection, treatment planning and post-treatment monitoring; [...]
Positive Interim Data from Cohorts 1 and 2 of Tenaya’s RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Demonstrated Consistent Reductions in Arrhythmia Burden for Adults with PKP2-associated ARVC
15/05/2026
All Patients Achieved Meaningful Decreases (Mean = 64%) in Daily Premature Ventricular Contraction Count TN-401 Gene Therapy was Well Tolerated at 3E13 vg/kg and 6E13 vg/kg Doses Post-dose Biopsies Provide Evidence of [...]
ARS Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Update
15/05/2026
Q1 2026 total revenue of $22.7 million including neffy ® (epinephrine nasal spray) U.S. net product revenue of $17.5 million CVS Caremark proposal in final stages of approval process; definitive update anticipated in [...]
Kymera Therapeutics Announces Presentations on KT-621, a First-In-Class, Oral STAT6 Degrader, at the Society for Investigative Dermatology and American Thoracic Society Congresses
15/05/2026
Late-breaking presentation at SID and featured presentation at the ATS Respiratory Innovation Summit highlight KT-621 BroADen Phase 1b clinical data and potential across Type 2 inflammatory diseases KT-621 parallel [...]
105,950 Orion Corporation A shares converted into B shares
15/05/2026
ORION CORPORATION STOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE 15 MAY 2026 at 9.00 EEST 105,950 Orion Corporation A shares converted into B shares In accordance with [...]
Desert Hope Treatment Center Welcomes Alumni Coordinator Whose Recovery Journey Began in Its Program
15/05/2026
LAS VEGAS, May 14, 2026 (GLOBE NEWSWIRE) -- Desert Hope Treatment Center, a leading addiction treatment center in Las Vegas, has appointed Madot (“Maddie”) Gebreegziabher as Alumni Coordinator. In her role, Maddie leads [...]
Medicus Pharma Reports First Quarter 2026 Financial Results and Provides Corporate Update
14/05/2026
Company Advances SkinJect® and Teverelix® Clinical Programs While Strengthening Financing Flexibility and Expanding Strategic Development Initiatives PHILADELPHIA, May 14, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. ( [...]
Fortress Biotech Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
14/05/2026
ZYCUBO ® approved by FDA to treat Menkes disease in the United States; Fortress subsidiary Cyprium Therapeutics closed the sale of its Rare Pediatric Disease Priority Review Voucher (PRV) for $205 million Fortress’ [...]
Ocugen, Inc. Announces Closing for $130.0 Million of 6.75% Convertible Senior Notes
14/05/2026
Includes Full Exercise of $15.0 million Over-Allotment Option MALVERN, Pa., May 14, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for [...]
HCW Biologics Reports First Quarter 2026 Business Highlights and Financial Results
14/05/2026
MIRAMAR, Fla., May 14, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on developing transformative fusion [...]
Serina Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates
14/05/2026
Phase 1b Registrational Clinical Study of SER-252 Underway in Advanced Parkinson’s Disease; TFL data from the SAD study arm targeted for first half of 2027 - – Closed $21.2 million private placement financing to support [...]
BIO GREEN MED SOLUTION REPORTS FIRST QUARTER FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
14/05/2026
KUALA LUMPUR, MALAYSIA, May 14, 2026 (GLOBE NEWSWIRE) -- Bio Green Med Solution, Inc. (NASDAQ: BGMS; “BGMS” or the “Company”), a diversified company engaged primarily in the provision of fire safety protection and [...]
Calidi Biotherapeutics Reports First Quarter 2026 Financial Results and Recent Operational Highlights
14/05/2026
Presented new data on CLD-401 at the AACR conference in San Diego, CA, detailing the profound immune changes in the tumor microenvironment induced by CLD-401; IND filing for CLD-401 expected by end of 2026 Presented new [...]

Pages